.png){kind=icon}
生物标志物溶液中心
我们广泛的全球实验室测试能力的科学思想领导和指导。在药物开发生命周期中提供定制的、端到端的生物标记解决方案。
行业见解让您的生物标志物战略前进。
博士级领导，可以扩展您的团队和/或帮助您制定全面的生物标志物战略
行业相关见解和专业治疗领域生物标记专业知识
Customized consultation for biomarker strategy solutions
利用a的好处biomarker strategy–包括从第一阶段成功过渡到监管批准的概率提高3倍1– early insights and thoughtful strategy design are critical. Continuity with a single partner, who understands and connects the science, can also enable more insightful clinical trial design and better clinical outcomes.
1BIO，Biomedtracker，Amplion 2016.pdf。www.bio.org网站
Whether you need support in building your biomarker program strategy or seek to extend your team with industry expertise, we can enable bringing your treatment to market more rapidly.
具有治疗领域专业知识的博士级领导
我们的Biomarker解决方案中心（BSC）专家与您合作，开发生物标志物策略和解决方案 - 从Discovery通过商业化 - 支持您的药物开发需求。我们可以识别差距，并提供缓解战略，以建立定制的战略，该策略整合在开发计划中整合治疗区域生物标志物和最佳实践。
BSC为以下领域拥有专业专业知识：
战略设计咨询
Designed to engage clients early in the drug development process, providing advice from need identification through project completion, the BSC team can help you address all of your biomarker questions to develop a customized approach for your biomarker program.
- Which is the most appropriate biomarker for my intended target?
- 什么是研究作用机制的最佳生物标志物？
- 生物标志物应该在哪里测量？
- Which regulatory environment and technology best support my intended use?
应在任何阶段进行进一步咨询药物开发的阶段，BSC团队也可以从事服务费或价值的基础。
Streamlined Navigation Support
The Biomarker Solution Center can help guide your program into one of the Covance/LabCorp extensive network of laboratories and regulatory environments. We can also work with you to transfer proprietary assays dependent on your needs – all while maintaining the scientific partnership of the BSC.
生物标志物开发的经验方法
利用我们在生物标志物方面的广泛、多学科的知识和治疗领域的专业知识，帮助定义和设计一个全面的生物标记物战略，专门为您的发展需求量身打造。无论您是在寻找特定的生物标志物，还是想探索可用的选项，我们的数据库中有4500个可用的分析和标记物，Covence和LabCorp都可以很容易地为您的计划找到合适的支持。
Suso J.Platero，PHD
Head, Biomarker Solution Center
全球领导者，精密医学，景观
SusoPlaters博士领导了生物标志物解决方案中心，为客户提供有生物标志的咨询和战略，可利用Covance和Labcorp实验室资源，以帮助发展生物标志物交付。他在20多年的经验中，与合同研究组织，诊断和制药行业和学术界以及联邦机构以及肿瘤和免疫肿瘤学的关键意见领导者。
Dr. Platero has contributed to the discovery of biomarkers and their application in clinical trials as well as the development of biomarkers to support companion diagnostics (CDx) and recently helped develop a companion diagnostic for a drug that was approved by the FDA in 2019. He served as the editor of the book,Molecular Pathology in Drug Discovery and Development, has authored numerous articles and holds four U.S. patents.
Akanksha Gupta，博士
Head of Immunology, Biomarker Solution Center
Akanksha Gupta博士为生物标志物解决方案中心提供免疫学治疗团队，该团队为客户提供生物标志物解决方案和战略，利用了康复和拉布洛普的实验室资源。她的战略领导能够为生物标志物战略提供科学方向，整合创新技术，新兴科学知识，临床可行性和监管要求，在包括免疫炎症，免疫肿瘤，呼吸道，皮肤病和其他自身免疫疾病，包括免疫炎症，免疫医学方法的精确药物方法。
古普塔博士拥有超过15年的制药行业经验，在药物开发、转化研究和早期至后期资产的支持发展战略方面具有丰富的经验。她分享了她作为30多篇同行评审的研究出版物、摘要和专利申请的作者或合著者的经验。
Katherine T.Landschulz博士
生物标记物解决方案中心心血管/代谢疾病主管
Katherine Landschulz博士在三大制药公司工作13年后于2010年加入科文斯，她在这些公司支持从发现到第三阶段的项目。在科文斯，她支持生物技术公司和大型制药公司进行生物标记物选择和战略开发，方法开发和鉴定/验证的实验室布局，可行性研究设计，并就药物开发中转化和探索性生物标记数据的使用提供建议。
博士的土地schulz has a wide range of experience in drug discovery and development, genomic and proteomic biomarker assay development, translational biomarkers, clinical pharmacogenomics and biomarker strategies for Diabetes/CV. She is the holder of two U.S. patents and has co-authored dozens of publications on across a wide range of therapeutic areas.
Maria J.Prendes，博士，理学硕士
Head of Oncology, Biomarker Solution Center
Maria Prendes博士领导生物标记物解决方案中心肿瘤治疗团队，并与客户一起指导临床试验中生物标记物的选择、鉴定和开发。她的职责还包括支持辅助诊断（CDx）的开发工作。
Specializing in the fields of immuno-oncology, cancer genetics, cancer biology and molecular oncology, Dr. Prendes has more than 15 years of experience in drug development where she directed research for the identification of new clinical biomarkers in oncology as well as designed, developed and characterized antibodies against specific biomarker targets to be used as therapeutic agents and for development of CDx assays. She is the holder of multiple U.S. patents and has authored and co-authored numerous journal articles.